Michael Schöll, PhD, University of Gothenburg, Gothenburg, Sweden, proposes a potential future diagnostic scenario for Alzheimer’s disease (AD) at the primary care level. Biomarkers suited to application in primary care settings must be scalable, accessible, and robust. Prof. Schöll highlights blood-based biomarkers and remotely administered cognitive testing as promising modalities in this space. Remotely administered cognitive testing, such as mobile app- or computer-based testing has numerous putative advantages: as well as being easy to implement, rapid, and cost effective, its use can be repeated over time to generate informative cognitive trajectories. Blood-based biomarkers are a huge focus currently, for use in clinical trial screening, intervention efficacy assessments, and minimally invasive diagnosis and monitoring. Prof. Schöll outlines the details of an upcoming study that will look into the use of blood-based and digital biomarkers for AD diagnosis, in which thousands of individuals will test their cognition at home over several months and give blood samples for biomarker profiling. This interview took place at the Alzheimer’s Research UK (ARUK) Conference 2023 in Aberdeen, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
